.jpg&w=3840&q=100)
Market
Insights
Reports delivered globally, covering a wide range of industries and sectors.
Clients who trust our expertise and rely on our insights for business decisions.
Managed Reports, ensuring seamless updates and premium service.
Satisfied Customers, committed to delivering exceptional value and quality.
Solid Tumor Testing Market 7.6 CAGR Growth Outlook 2025-2033
Solid Tumor Testing Market by Type (Genetic testing, Conventional testing), by Application (Breast cancer, Lung cancer, Prostate cancer, Colorectal cancer, Melanoma, Other applications), by End-users (Hospitals, Diagnostic laboratories, Cancer research institutes, Other end-users), by North America (U.S., Canada), by Europe (Germany, UK, France, Spain, Italy, Netherlands, Rest of Europe), by Asia Pacific (China, Japan, India, Australia, South Korea, Rest of Asia Pacific), by Latin America (Brazil, Mexico, Argentina, Rest of Latin America), by Middle East and Africa (South Africa, Saudi Arabia, UAE, Rest of Middle East and Africa) Forecast 2025-2033
Solid Tumor Testing Market 7.6 CAGR Growth Outlook 2025-2033
Key Insights
The size of the Solid Tumor Testing Market market was valued at USD 20.5 Billion in 2024 and is projected to reach USD 34.23 Billion by 2033, with an expected CAGR of 7.6% during the forecast period. The growth of the Solid Tumor Testing Market is also influenced by the increasing prevalence of cancer and advancement in molecular diagnostics. Solid tumor testing is used to analyze the tumor tissues and identify genetic mutations, biomarkers, and molecular changes that assist in diagnosis, prognosis, and personalized treatment strategies. The rising adoption of NGS, PCR, and in situ hybridization techniques has dramatically changed the dynamics of cancer diagnostics. Growing awareness about the early detection of cancer, and the demand for targeted therapies are driving the expansion of the market. The expansion of precision medicine and companion diagnostics is further promoting the demand for solid tumor testing. Government research initiatives on cancer and the further development of techniques in liquid biopsies contribute to the market growth. Market expansion may face challenges in terms of high cost of testing, regulatory hurdles, and reimbursement limitation. North America is the leading region in this market due to its developed healthcare infrastructure and extensive research in oncology, followed by Europe and the Asia-Pacific region. The adoption of AI-driven diagnostic tools and bioinformatics solutions helps increase efficiency in tumor testing. Hospital, diagnostic laboratories, and research institutes are the prime end-users of solid tumor testing solutions. The incorporation of automation in laboratory workflows has improved the accuracy of tests, as well as the turnaround time. The non-invasive test through liquid biopsies is becoming a fast-emerging and more viable alternative to the traditional tissue biopsy. Increasing investments in oncology diagnostics in emerging markets have further fueled market growth. Continuous innovations in the area of genomic profiling and biomarker discovery are expected to create new opportunities for players in the market. Advances in multi-gene panels and tumor mutation burden (TMB) analysis are significantly improving cancer detection and treatment decisions.
Solid Tumor Testing Market Concentration & Characteristics
The market is moderately concentrated, with a few major players accounting for a significant portion of the market share. Key players include Abbott, Agilent Technologies, Caris Life Sciences, F. Hoffmann-La Roche Ltd, Foundation Medicine, Guardant Health, Hologic, Inc., Illumina, Inc., MedGenome, Myriad Genetics, NeoGenomics Laboratories, QIAGEN, Quest Diagnostics Incorporated, SOPHiA GENETICS, and Thermo Fisher Scientific, Inc.
Solid Tumor Testing Market Trends
- Increased adoption of next-generation sequencing (NGS): NGS enables the comprehensive genetic analysis of solid tumors, providing valuable information for treatment selection and prognosis.
- Development of novel biomarkers: The identification of specific genetic alterations and protein markers associated with different types of solid tumors has led to the development of targeted therapies and companion diagnostic tests.
- Growing emphasis on personalized medicine: Solid tumor testing plays a crucial role in tailoring treatments to the specific molecular characteristics of individual patients, maximizing therapeutic efficacy and minimizing side effects.
- Advancements in liquid biopsy: Liquid biopsy technologies offer a minimally invasive approach to detect tumor-specific biomarkers in circulating cell-free nucleic acids or circulating tumor cells, allowing for real-time monitoring of treatment response.
- Integration of artificial intelligence (AI): AI algorithms are being applied to improve the interpretation of solid tumor testing results, providing automated detection and classification of genetic alterations and facilitating the selection of optimal treatment strategies.
Key Region or Country & Segment to Dominate the Market
Key Region: North America is expected to hold the largest market share due to the high prevalence of cancer, advanced healthcare infrastructure, and favorable regulatory policies.
Dominant Segment: Next-generation sequencing (NGS) is expected to dominate the market, driven by its comprehensive genetic analysis capabilities and growing adoption in precision oncology.
Solid Tumor Testing Market Product Insights Report Coverage & Deliverables
The report provides comprehensive insights into the Solid Tumor Testing market, including detailed market sizing, market share analysis, and forecast for the period 2023-2030. It covers the following key aspects:
- Market overview and dynamics
- Product segments and applications
- Regional analysis
- Competitive landscape
- Key trends and drivers
- Market opportunities and challenges
Solid Tumor Testing Market Analysis
The global solid tumor testing market is expected to reach USD 42.3 billion by 2030, growing at a CAGR of 7.6% from 2023 to 2030. North America held the largest market share of 35% in 2023 and is projected to continue dominating the market during the forecast period. Asia Pacific is expected to exhibit the highest growth rate, driven by factors such as rising cancer incidence, increasing healthcare expenditure, and government initiatives promoting personalized medicine.
Solid Tumor Testing Market Regional Insights
North America
- U.S.
- Canada
Europe
- Germany
- UK
- France
- Spain
- Italy
- Netherlands
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia Pacific
Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
Middle East and Africa
- South Africa
- Saudi Arabia
- UAE
- Rest of Middle East and Africa
Driving Forces: What's Propelling the Solid Tumor Testing Market
- Increasing incidence of cancer
- Technological advancements in molecular diagnostics
- Growing awareness about personalized medicine
- Favorable government initiatives
Challenges and Restraints in Solid Tumor Testing Market
- High cost of testing
- Limited reimbursement policies
- Ethical concerns related to genetic testing
Emerging Trends in Solid Tumor Testing Market
- Integration of AI in testing and interpretation
- Development of minimally invasive liquid biopsy technologies
- Growing focus on companion diagnostics
- Expansion of personalized medicine in low- and middle-income countries
Solid Tumor Testing Industry News
- August 2024: Illumina, Inc. announced the Food and Drug Administration (FDA) approval for its TruSight Oncology (TSO) Comprehensive test, an in-vitro diagnostic testing. This approval is expected to increase the company's competitiveness in the market and enhance its reputation.
- March 2023: NeoGenomics, Inc. announced the expansion of its next-generation sequencing (NGS) portfolio with the commercial availability of multiple innovative tests, including the Neo Comprehensive - solid tumor test, which provides a comprehensive genomic profile (CGP) for solid tumor cancers, and the Neo Comprehensive - Myeloid disorders test for myeloid neoplasms. This expansion enhanced the company's product offerings, allowing them to provide a broader spectrum of advanced genomic testing solutions.
Leading Players in the Solid Tumor Testing Market Keyword
- Abbott
- Agilent Technologies
- Caris Life Sciences
- F. Hoffmann-La Roche Ltd
- Foundation Medicine
- Guardant Health
- Hologic, Inc.
- Illumina, Inc.
- MedGenome
- Myriad Genetics
- NeoGenomics Laboratories
- QIAGEN
- Quest Diagnostics Incorporated
- SOPHiA GENETICS
- Thermo Fisher Scientific
Solid Tumor Testing Market Segmentation
- 1. Type
- 1.1. Genetic testing
- 1.2. Conventional testing
- 2. Application
- 2.1. Breast cancer
- 2.2. Lung cancer
- 2.3. Prostate cancer
- 2.4. Colorectal cancer
- 2.5. Melanoma
- 2.6. Other applications
- 3. End-users
- 3.1. Hospitals
- 3.2. Diagnostic laboratories
- 3.3. Cancer research institutes
- 3.4. Other end-users
Solid Tumor Testing Market Segmentation By Geography
- 1. North America
- 1.1. U.S.
- 1.2. Canada
- 2. Europe
- 2.1. Germany
- 2.2. UK
- 2.3. France
- 2.4. Spain
- 2.5. Italy
- 2.6. Netherlands
- 2.7. Rest of Europe
- 3. Asia Pacific
- 3.1. China
- 3.2. Japan
- 3.3. India
- 3.4. Australia
- 3.5. South Korea
- 3.6. Rest of Asia Pacific
- 4. Latin America
- 4.1. Brazil
- 4.2. Mexico
- 4.3. Argentina
- 4.4. Rest of Latin America
- 5. Middle East and Africa
- 5.1. South Africa
- 5.2. Saudi Arabia
- 5.3. UAE
- 5.4. Rest of Middle East and Africa
Solid Tumor Testing Market REPORT HIGHLIGHTS
| Aspects | Details |
|---|---|
| Study Period | 2019-2033 |
| Base Year | 2024 |
| Estimated Year | 2025 |
| Forecast Period | 2025-2033 |
| Historical Period | 2019-2024 |
| Growth Rate | CAGR of 7.6% from 2019-2033 |
| Segmentation |
|
- 1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
- 2. Executive Summary
- 2.1. Introduction
- 3. Market Dynamics
- 3.1. Introduction
- 3.2. Market Drivers
- 3.2.1 Rising cancer incidences
- 3.2.2 Advancements in diagnostic technologies
- 3.2.3 Growing awareness and demand
- 3.2.4 Increased healthcare expenditure and investments
- 3.3. Market Restrains
- 3.3.1. High capital requirements
- 3.4. Market Trends
- 4. Market Factor Analysis
- 4.1. Porters Five Forces
- 4.2. Supply/Value Chain
- 4.3. PESTEL analysis
- 4.4. Market Entropy
- 4.5. Patent/Trademark Analysis
- 5. Global Solid Tumor Testing Market Analysis, Insights and Forecast, 2019-2031
- 5.1. Market Analysis, Insights and Forecast - by Type
- 5.1.1. Genetic testing
- 5.1.2. Conventional testing
- 5.2. Market Analysis, Insights and Forecast - by Application
- 5.2.1. Breast cancer
- 5.2.2. Lung cancer
- 5.2.3. Prostate cancer
- 5.2.4. Colorectal cancer
- 5.2.5. Melanoma
- 5.2.6. Other applications
- 5.3. Market Analysis, Insights and Forecast - by End-users
- 5.3.1. Hospitals
- 5.3.2. Diagnostic laboratories
- 5.3.3. Cancer research institutes
- 5.3.4. Other end-users
- 5.4. Market Analysis, Insights and Forecast - by Region
- 5.4.1. North America
- 5.4.2. Europe
- 5.4.3. Asia Pacific
- 5.4.4. Latin America
- 5.4.5. Middle East and Africa
- 5.1. Market Analysis, Insights and Forecast - by Type
- 6. North America Solid Tumor Testing Market Analysis, Insights and Forecast, 2019-2031
- 6.1. Market Analysis, Insights and Forecast - by Type
- 6.1.1. Genetic testing
- 6.1.2. Conventional testing
- 6.2. Market Analysis, Insights and Forecast - by Application
- 6.2.1. Breast cancer
- 6.2.2. Lung cancer
- 6.2.3. Prostate cancer
- 6.2.4. Colorectal cancer
- 6.2.5. Melanoma
- 6.2.6. Other applications
- 6.3. Market Analysis, Insights and Forecast - by End-users
- 6.3.1. Hospitals
- 6.3.2. Diagnostic laboratories
- 6.3.3. Cancer research institutes
- 6.3.4. Other end-users
- 6.1. Market Analysis, Insights and Forecast - by Type
- 7. Europe Solid Tumor Testing Market Analysis, Insights and Forecast, 2019-2031
- 7.1. Market Analysis, Insights and Forecast - by Type
- 7.1.1. Genetic testing
- 7.1.2. Conventional testing
- 7.2. Market Analysis, Insights and Forecast - by Application
- 7.2.1. Breast cancer
- 7.2.2. Lung cancer
- 7.2.3. Prostate cancer
- 7.2.4. Colorectal cancer
- 7.2.5. Melanoma
- 7.2.6. Other applications
- 7.3. Market Analysis, Insights and Forecast - by End-users
- 7.3.1. Hospitals
- 7.3.2. Diagnostic laboratories
- 7.3.3. Cancer research institutes
- 7.3.4. Other end-users
- 7.1. Market Analysis, Insights and Forecast - by Type
- 8. Asia Pacific Solid Tumor Testing Market Analysis, Insights and Forecast, 2019-2031
- 8.1. Market Analysis, Insights and Forecast - by Type
- 8.1.1. Genetic testing
- 8.1.2. Conventional testing
- 8.2. Market Analysis, Insights and Forecast - by Application
- 8.2.1. Breast cancer
- 8.2.2. Lung cancer
- 8.2.3. Prostate cancer
- 8.2.4. Colorectal cancer
- 8.2.5. Melanoma
- 8.2.6. Other applications
- 8.3. Market Analysis, Insights and Forecast - by End-users
- 8.3.1. Hospitals
- 8.3.2. Diagnostic laboratories
- 8.3.3. Cancer research institutes
- 8.3.4. Other end-users
- 8.1. Market Analysis, Insights and Forecast - by Type
- 9. Latin America Solid Tumor Testing Market Analysis, Insights and Forecast, 2019-2031
- 9.1. Market Analysis, Insights and Forecast - by Type
- 9.1.1. Genetic testing
- 9.1.2. Conventional testing
- 9.2. Market Analysis, Insights and Forecast - by Application
- 9.2.1. Breast cancer
- 9.2.2. Lung cancer
- 9.2.3. Prostate cancer
- 9.2.4. Colorectal cancer
- 9.2.5. Melanoma
- 9.2.6. Other applications
- 9.3. Market Analysis, Insights and Forecast - by End-users
- 9.3.1. Hospitals
- 9.3.2. Diagnostic laboratories
- 9.3.3. Cancer research institutes
- 9.3.4. Other end-users
- 9.1. Market Analysis, Insights and Forecast - by Type
- 10. Middle East and Africa Solid Tumor Testing Market Analysis, Insights and Forecast, 2019-2031
- 10.1. Market Analysis, Insights and Forecast - by Type
- 10.1.1. Genetic testing
- 10.1.2. Conventional testing
- 10.2. Market Analysis, Insights and Forecast - by Application
- 10.2.1. Breast cancer
- 10.2.2. Lung cancer
- 10.2.3. Prostate cancer
- 10.2.4. Colorectal cancer
- 10.2.5. Melanoma
- 10.2.6. Other applications
- 10.3. Market Analysis, Insights and Forecast - by End-users
- 10.3.1. Hospitals
- 10.3.2. Diagnostic laboratories
- 10.3.3. Cancer research institutes
- 10.3.4. Other end-users
- 10.1. Market Analysis, Insights and Forecast - by Type
- 11. Competitive Analysis
- 11.1. Global Market Share Analysis 2024
- 11.2. Company Profiles
- 11.2.1 Abbott
- 11.2.1.1. Overview
- 11.2.1.2. Products
- 11.2.1.3. SWOT Analysis
- 11.2.1.4. Recent Developments
- 11.2.1.5. Financials (Based on Availability)
- 11.2.2 Agilent Technologies Inc.
- 11.2.2.1. Overview
- 11.2.2.2. Products
- 11.2.2.3. SWOT Analysis
- 11.2.2.4. Recent Developments
- 11.2.2.5. Financials (Based on Availability)
- 11.2.3 Caris Life Sciences
- 11.2.3.1. Overview
- 11.2.3.2. Products
- 11.2.3.3. SWOT Analysis
- 11.2.3.4. Recent Developments
- 11.2.3.5. Financials (Based on Availability)
- 11.2.4 F. Hoffmann-La Roche Ltd
- 11.2.4.1. Overview
- 11.2.4.2. Products
- 11.2.4.3. SWOT Analysis
- 11.2.4.4. Recent Developments
- 11.2.4.5. Financials (Based on Availability)
- 11.2.5 Foundation Medicine Inc.
- 11.2.5.1. Overview
- 11.2.5.2. Products
- 11.2.5.3. SWOT Analysis
- 11.2.5.4. Recent Developments
- 11.2.5.5. Financials (Based on Availability)
- 11.2.6 Guardant Health
- 11.2.6.1. Overview
- 11.2.6.2. Products
- 11.2.6.3. SWOT Analysis
- 11.2.6.4. Recent Developments
- 11.2.6.5. Financials (Based on Availability)
- 11.2.7 Hologic Inc.
- 11.2.7.1. Overview
- 11.2.7.2. Products
- 11.2.7.3. SWOT Analysis
- 11.2.7.4. Recent Developments
- 11.2.7.5. Financials (Based on Availability)
- 11.2.8 Illumina Inc.
- 11.2.8.1. Overview
- 11.2.8.2. Products
- 11.2.8.3. SWOT Analysis
- 11.2.8.4. Recent Developments
- 11.2.8.5. Financials (Based on Availability)
- 11.2.9 MedGenome
- 11.2.9.1. Overview
- 11.2.9.2. Products
- 11.2.9.3. SWOT Analysis
- 11.2.9.4. Recent Developments
- 11.2.9.5. Financials (Based on Availability)
- 11.2.10 Myriad Genetics Inc.
- 11.2.10.1. Overview
- 11.2.10.2. Products
- 11.2.10.3. SWOT Analysis
- 11.2.10.4. Recent Developments
- 11.2.10.5. Financials (Based on Availability)
- 11.2.11 NeoGenomics Laboratories
- 11.2.11.1. Overview
- 11.2.11.2. Products
- 11.2.11.3. SWOT Analysis
- 11.2.11.4. Recent Developments
- 11.2.11.5. Financials (Based on Availability)
- 11.2.12 QIAGEN
- 11.2.12.1. Overview
- 11.2.12.2. Products
- 11.2.12.3. SWOT Analysis
- 11.2.12.4. Recent Developments
- 11.2.12.5. Financials (Based on Availability)
- 11.2.13 Quest Diagnostics Incorporated
- 11.2.13.1. Overview
- 11.2.13.2. Products
- 11.2.13.3. SWOT Analysis
- 11.2.13.4. Recent Developments
- 11.2.13.5. Financials (Based on Availability)
- 11.2.14 SOPHiA GENETICS
- 11.2.14.1. Overview
- 11.2.14.2. Products
- 11.2.14.3. SWOT Analysis
- 11.2.14.4. Recent Developments
- 11.2.14.5. Financials (Based on Availability)
- 11.2.15 Thermo Fisher Scientific Inc.
- 11.2.15.1. Overview
- 11.2.15.2. Products
- 11.2.15.3. SWOT Analysis
- 11.2.15.4. Recent Developments
- 11.2.15.5. Financials (Based on Availability)
- 11.2.1 Abbott
- Figure 1: Global Solid Tumor Testing Market Revenue Breakdown (Billion, %) by Region 2024 & 2032
- Figure 2: North America Solid Tumor Testing Market Revenue (Billion), by Type 2024 & 2032
- Figure 3: North America Solid Tumor Testing Market Revenue Share (%), by Type 2024 & 2032
- Figure 4: North America Solid Tumor Testing Market Revenue (Billion), by Application 2024 & 2032
- Figure 5: North America Solid Tumor Testing Market Revenue Share (%), by Application 2024 & 2032
- Figure 6: North America Solid Tumor Testing Market Revenue (Billion), by End-users 2024 & 2032
- Figure 7: North America Solid Tumor Testing Market Revenue Share (%), by End-users 2024 & 2032
- Figure 8: North America Solid Tumor Testing Market Revenue (Billion), by Country 2024 & 2032
- Figure 9: North America Solid Tumor Testing Market Revenue Share (%), by Country 2024 & 2032
- Figure 10: Europe Solid Tumor Testing Market Revenue (Billion), by Type 2024 & 2032
- Figure 11: Europe Solid Tumor Testing Market Revenue Share (%), by Type 2024 & 2032
- Figure 12: Europe Solid Tumor Testing Market Revenue (Billion), by Application 2024 & 2032
- Figure 13: Europe Solid Tumor Testing Market Revenue Share (%), by Application 2024 & 2032
- Figure 14: Europe Solid Tumor Testing Market Revenue (Billion), by End-users 2024 & 2032
- Figure 15: Europe Solid Tumor Testing Market Revenue Share (%), by End-users 2024 & 2032
- Figure 16: Europe Solid Tumor Testing Market Revenue (Billion), by Country 2024 & 2032
- Figure 17: Europe Solid Tumor Testing Market Revenue Share (%), by Country 2024 & 2032
- Figure 18: Asia Pacific Solid Tumor Testing Market Revenue (Billion), by Type 2024 & 2032
- Figure 19: Asia Pacific Solid Tumor Testing Market Revenue Share (%), by Type 2024 & 2032
- Figure 20: Asia Pacific Solid Tumor Testing Market Revenue (Billion), by Application 2024 & 2032
- Figure 21: Asia Pacific Solid Tumor Testing Market Revenue Share (%), by Application 2024 & 2032
- Figure 22: Asia Pacific Solid Tumor Testing Market Revenue (Billion), by End-users 2024 & 2032
- Figure 23: Asia Pacific Solid Tumor Testing Market Revenue Share (%), by End-users 2024 & 2032
- Figure 24: Asia Pacific Solid Tumor Testing Market Revenue (Billion), by Country 2024 & 2032
- Figure 25: Asia Pacific Solid Tumor Testing Market Revenue Share (%), by Country 2024 & 2032
- Figure 26: Latin America Solid Tumor Testing Market Revenue (Billion), by Type 2024 & 2032
- Figure 27: Latin America Solid Tumor Testing Market Revenue Share (%), by Type 2024 & 2032
- Figure 28: Latin America Solid Tumor Testing Market Revenue (Billion), by Application 2024 & 2032
- Figure 29: Latin America Solid Tumor Testing Market Revenue Share (%), by Application 2024 & 2032
- Figure 30: Latin America Solid Tumor Testing Market Revenue (Billion), by End-users 2024 & 2032
- Figure 31: Latin America Solid Tumor Testing Market Revenue Share (%), by End-users 2024 & 2032
- Figure 32: Latin America Solid Tumor Testing Market Revenue (Billion), by Country 2024 & 2032
- Figure 33: Latin America Solid Tumor Testing Market Revenue Share (%), by Country 2024 & 2032
- Figure 34: Middle East and Africa Solid Tumor Testing Market Revenue (Billion), by Type 2024 & 2032
- Figure 35: Middle East and Africa Solid Tumor Testing Market Revenue Share (%), by Type 2024 & 2032
- Figure 36: Middle East and Africa Solid Tumor Testing Market Revenue (Billion), by Application 2024 & 2032
- Figure 37: Middle East and Africa Solid Tumor Testing Market Revenue Share (%), by Application 2024 & 2032
- Figure 38: Middle East and Africa Solid Tumor Testing Market Revenue (Billion), by End-users 2024 & 2032
- Figure 39: Middle East and Africa Solid Tumor Testing Market Revenue Share (%), by End-users 2024 & 2032
- Figure 40: Middle East and Africa Solid Tumor Testing Market Revenue (Billion), by Country 2024 & 2032
- Figure 41: Middle East and Africa Solid Tumor Testing Market Revenue Share (%), by Country 2024 & 2032
- Table 1: Global Solid Tumor Testing Market Revenue Billion Forecast, by Region 2019 & 2032
- Table 2: Global Solid Tumor Testing Market Revenue Billion Forecast, by Type 2019 & 2032
- Table 3: Global Solid Tumor Testing Market Revenue Billion Forecast, by Application 2019 & 2032
- Table 4: Global Solid Tumor Testing Market Revenue Billion Forecast, by End-users 2019 & 2032
- Table 5: Global Solid Tumor Testing Market Revenue Billion Forecast, by Region 2019 & 2032
- Table 6: Global Solid Tumor Testing Market Revenue Billion Forecast, by Type 2019 & 2032
- Table 7: Global Solid Tumor Testing Market Revenue Billion Forecast, by Application 2019 & 2032
- Table 8: Global Solid Tumor Testing Market Revenue Billion Forecast, by End-users 2019 & 2032
- Table 9: Global Solid Tumor Testing Market Revenue Billion Forecast, by Country 2019 & 2032
- Table 10: U.S. Solid Tumor Testing Market Revenue (Billion) Forecast, by Application 2019 & 2032
- Table 11: Canada Solid Tumor Testing Market Revenue (Billion) Forecast, by Application 2019 & 2032
- Table 12: Global Solid Tumor Testing Market Revenue Billion Forecast, by Type 2019 & 2032
- Table 13: Global Solid Tumor Testing Market Revenue Billion Forecast, by Application 2019 & 2032
- Table 14: Global Solid Tumor Testing Market Revenue Billion Forecast, by End-users 2019 & 2032
- Table 15: Global Solid Tumor Testing Market Revenue Billion Forecast, by Country 2019 & 2032
- Table 16: Germany Solid Tumor Testing Market Revenue (Billion) Forecast, by Application 2019 & 2032
- Table 17: UK Solid Tumor Testing Market Revenue (Billion) Forecast, by Application 2019 & 2032
- Table 18: France Solid Tumor Testing Market Revenue (Billion) Forecast, by Application 2019 & 2032
- Table 19: Spain Solid Tumor Testing Market Revenue (Billion) Forecast, by Application 2019 & 2032
- Table 20: Italy Solid Tumor Testing Market Revenue (Billion) Forecast, by Application 2019 & 2032
- Table 21: Netherlands Solid Tumor Testing Market Revenue (Billion) Forecast, by Application 2019 & 2032
- Table 22: Rest of Europe Solid Tumor Testing Market Revenue (Billion) Forecast, by Application 2019 & 2032
- Table 23: Global Solid Tumor Testing Market Revenue Billion Forecast, by Type 2019 & 2032
- Table 24: Global Solid Tumor Testing Market Revenue Billion Forecast, by Application 2019 & 2032
- Table 25: Global Solid Tumor Testing Market Revenue Billion Forecast, by End-users 2019 & 2032
- Table 26: Global Solid Tumor Testing Market Revenue Billion Forecast, by Country 2019 & 2032
- Table 27: China Solid Tumor Testing Market Revenue (Billion) Forecast, by Application 2019 & 2032
- Table 28: Japan Solid Tumor Testing Market Revenue (Billion) Forecast, by Application 2019 & 2032
- Table 29: India Solid Tumor Testing Market Revenue (Billion) Forecast, by Application 2019 & 2032
- Table 30: Australia Solid Tumor Testing Market Revenue (Billion) Forecast, by Application 2019 & 2032
- Table 31: South Korea Solid Tumor Testing Market Revenue (Billion) Forecast, by Application 2019 & 2032
- Table 32: Rest of Asia Pacific Solid Tumor Testing Market Revenue (Billion) Forecast, by Application 2019 & 2032
- Table 33: Global Solid Tumor Testing Market Revenue Billion Forecast, by Type 2019 & 2032
- Table 34: Global Solid Tumor Testing Market Revenue Billion Forecast, by Application 2019 & 2032
- Table 35: Global Solid Tumor Testing Market Revenue Billion Forecast, by End-users 2019 & 2032
- Table 36: Global Solid Tumor Testing Market Revenue Billion Forecast, by Country 2019 & 2032
- Table 37: Brazil Solid Tumor Testing Market Revenue (Billion) Forecast, by Application 2019 & 2032
- Table 38: Mexico Solid Tumor Testing Market Revenue (Billion) Forecast, by Application 2019 & 2032
- Table 39: Argentina Solid Tumor Testing Market Revenue (Billion) Forecast, by Application 2019 & 2032
- Table 40: Rest of Latin America Solid Tumor Testing Market Revenue (Billion) Forecast, by Application 2019 & 2032
- Table 41: Global Solid Tumor Testing Market Revenue Billion Forecast, by Type 2019 & 2032
- Table 42: Global Solid Tumor Testing Market Revenue Billion Forecast, by Application 2019 & 2032
- Table 43: Global Solid Tumor Testing Market Revenue Billion Forecast, by End-users 2019 & 2032
- Table 44: Global Solid Tumor Testing Market Revenue Billion Forecast, by Country 2019 & 2032
- Table 45: South Africa Solid Tumor Testing Market Revenue (Billion) Forecast, by Application 2019 & 2032
- Table 46: Saudi Arabia Solid Tumor Testing Market Revenue (Billion) Forecast, by Application 2019 & 2032
- Table 47: UAE Solid Tumor Testing Market Revenue (Billion) Forecast, by Application 2019 & 2032
- Table 48: Rest of Middle East and Africa Solid Tumor Testing Market Revenue (Billion) Forecast, by Application 2019 & 2032
STEP 1 - Identification of Relevant Samples Size from Population Database
STEP 2 - Approaches for Defining Global Market Size (Value, Volume* & Price*)
Note* : In applicable scenarios
STEP 3 - Data Sources
Primary Research
- Web Analytics
- Survey Reports
- Research Institute
- Latest Research Reports
- Opinion Leaders
Secondary Research
- Annual Reports
- White Paper
- Latest Press Release
- Industry Association
- Paid Database
- Investor Presentations
STEP 4 - Data Triangulation
Involves using different sources of information in order to increase the validity of a study
These sources are likely to be stakeholders in a program - participants, other researchers, program staff, other community members, and so on.
Then we put all data in single framework & apply various statistical tools to find out the dynamic on the market.
During the analysis stage, feedback from the stakeholder groups would be compared to determine areas of agreement as well as areas of divergence
Frequently Asked Questions
What are some drivers contributing to market growth?
Rising cancer incidences., Advancements in diagnostic technologies., Growing awareness and demand., Increased healthcare expenditure and investments.
Can you provide details about the market size?
The market size is estimated to be USD 20.5 Billion as of 2022.
Can you provide examples of recent developments in the market?
In August 2024, Illumina, Inc., announced the Food and Drug Administration (FDA) approval for its TruSight Oncology (TSO) Comprehensive test, an in-vitro diagnostic testing. This approval is expected to increase the company’s competitiveness in the market and enhance its reputation.
What are the main segments of the Solid Tumor Testing Market?
The market segments include Type, Application, End-users
Are there any additional resources or data provided in the report?
While the report offers comprehensive insights, it's advisable to review the specific contents or supplementary materials provided to ascertain if additional resources or data are available.
Which companies are prominent players in the Solid Tumor Testing Market?
Key companies in the market include Abbott,Agilent Technologies, Inc.,Caris Life Sciences,F. Hoffmann-La Roche Ltd,Foundation Medicine, Inc.,Guardant Health,Hologic, Inc.,Illumina, Inc.,MedGenome,Myriad Genetics, Inc.,NeoGenomics Laboratories,QIAGEN,Quest Diagnostics Incorporated,SOPHiA GENETICS,Thermo Fisher Scientific, Inc.
How can I stay updated on further developments or reports in the Solid Tumor Testing Market?
To stay informed about further developments, trends, and reports in the Solid Tumor Testing Market, consider subscribing to industry newsletters, following relevant companies and organizations, or regularly checking reputable industry news sources and publications.
How do I determine which pricing option suits my needs best?
The pricing options vary based on user requirements and access needs. Individual users may opt for single-user licenses, while businesses requiring broader access may choose multi-user or enterprise licenses for cost-effective access to the report.
Related Reports
See the similar reports
About Market Insights Report
Market Insights Reports offers comprehensive market research reports and analysis, giving businesses important information about their clients, rivals, and sector to help them make well-informed decisions on operations, marketing, and business strategy. We offer a variety of services in addition to market research, data analysis, and strategy planning. In order to find opportunities and learn more about our competitors and the industry at large, we employ competitive analysis. To identify areas for development, we also evaluate our performance against that of our rivals. We can determine the places at which we can offer our clients the most value by performing value chain analysis.
Additionally, clients receive a thorough overview of their industry business environment. We can find trends that help us forecast future possibilities and threats by examining global macroeconomic dynamics and consumer behavior patterns. By analyzing their features and advantages, contrasting them with comparable items on the market, and evaluating both their quantitative and qualitative performance, we comprehensively evaluate our clients' products. This allows us to assist customers in determining how their goods compare to those of their rivals and in creating successful marketing plans. Our group has been successful in gaining a thorough grasp of our clients' requirements and offering them creative solutions. We currently provide services to more than 50 nations in Europe, the Middle East, Africa, Latin America, Asia Pacific, and North America. Because of our global reach, we have been able to establish trusting bonds with our partners and clients in various nations, improving customer service and forging a more cohesive worldwide presence.